Consequently, animal model studieshave identified isoform-selective inhibitors targeting CAs as potentialdrug candidates for addressing several disorders.7,8 Simultaneously,other studies have provided insight into carbonic anhydrases (CAs)as potential novel targets for the therapy of Alzheimer’s disease(AD).9,10 The elevated amounts of CA II detected inboth the central and peripheral systems indicate that the expressionof CA II might potentially serve as a biomarker for cognitive problems.11 Here, CA2 is linked to early-onset autosomal dominant Alzheimer disease.